GCM
MRTX

Glenview Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Glenview Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-203,800
Closed -$13.7M – 62
2022
Q2 		$13.7M Buy
203,800
+87,690
+76% +$5.58M 0.34% 40
2022
Q1 		$9.55M Buy
116,110
+70,310
+154% +$7.19M 0.19% 49
2021
Q4 		$6.72M Hold
45,800
– – 0.14% 52
2021
Q3 		$8.1M Buy
+45,800
New +$7.37M 0.15% 55

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Glenview Capital Management's MRTX Position: Q3 2022 in Review

Glenview Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2022, closing a stake of 203,800 shares — an estimated $13.7M sold.

Glenview Capital Management first reported a position in MRTX in Q3 2021 and held it in 4 quarters. The position peaked at $13.7M in Q2 2022. 243 funds tracked by Wall St. Rank hold MRTX as of Q3 2022.

  • Glenview Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Glenview Capital Management sold 203,800 Mirati Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $13.7M.
  • Glenview Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2021 and held it in 4 quarters.
  • Glenview Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $13.7M in Q2 2022.
  • 243 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Glenview Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.